Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Champions Oncology, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −2 vs. Q1 2024
- Shares held
- 5.77M
- +140.5K (+2.5%) vs. Q1 2024
- Total value
- $29.9M
- +$2.25M (+8.2%) vs. Q1 2024
- New holders
- 0
- 7 more added
- Sold out
- 2
- 7 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CSBR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 28 | $36.3M |
| Q1 2026 | 25 | $33.0M |
| Q4 2025 | 27 | $39.7M |
| Q3 2025 | 27 | $36.7M |
| Q2 2025 | 30 | $42.5M |
| Q1 2025 | 34 | $51.4M |
| Q4 2024 | 25 | $49.0M |
| Q3 2024 | 22 | $28.2M |
| Q2 2024 | 23 | $29.9M |
| Q1 2024 | 25 | $27.6M |
| Q4 2023 | 23 | $31.5M |
| Q3 2023 | 29 | $35.6M |
| Q2 2023 | 28 | $37.0M |
| Q1 2023 | 30 | $23.6M |
| Q4 2022 | 29 | $27.1M |
| Q3 2022 | 32 | $46.8M |
| Q2 2022 | 32 | $49.8M |
| Q1 2022 | 30 | $50.4M |
| Q4 2021 | 31 | $51.7M |
| Q3 2021 | 35 | $64.1M |
| Q2 2021 | 38 | $68.5M |
| Q1 2021 | 45 | $81.4M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Champions Oncology, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Battery Management Corp. | 2,421,673 | $12.5M | 3.29% | 00.0% | Unchanged |
| NEA Management Company, LLC | 1,713,720 | $8.86M | 0.67% | 00.0% | Unchanged |
| Tocqueville Asset Management L.P. | 684,628 | $3.54M | 0.06% | 00.0% | Unchanged |
| Vanguard Group Inc | 307,002 | $1.59M | 0.00% | +221,398+258.6% | Added |
| Renaissance Technologies LLC | 122,591 | $633.8K | 0.00% | −2,100−1.7% | Reduced |
| BlackRock Inc. | 116,072 | $600.1K | 0.00% | +389+0.3% | Added |
| Goldman Sachs Group Inc | 69,304 | $358.3K | 0.00% | +30.0% | Added |
| Geode Capital Management, LLC | 63,086 | $326.2K | 0.00% | +972+1.6% | Added |
| Morgan Stanley | 43,100 | $222.8K | 0.00% | +2,400+5.9% | Added |
| Northern Trust Corp | 40,463 | $209.2K | 0.00% | −2,226−5.2% | Reduced |
| HighTower Advisors, LLC | 34,308 | $178.0K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 30,697 | $157.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 26,749 | $138.3K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 26,553 | $137.3K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 25,273 | $130.7K | 0.00% | −553−2.1% | Reduced |
| Cambridge Investment Research Advisors, Inc. | 12,252 | $63.0K | 0.00% | 00.0% | Unchanged |
| Mesirow Financial Investment Management, Inc. | 12,000 | $62.0K | 0.00% | −380−3.1% | Reduced |
| Stifel Financial Corp | 10,942 | $56.6K | 0.00% | −250−2.2% | Reduced |
| Citadel Advisors LLC | 10,218 | $52.8K | 0.00% | −2,607−20.3% | Reduced |
| Simplex Trading, LLC | 3,004 | $15.0K | 0.00% | +1,407+88.1% | Added |
| UBS Group AG | 379 | $1.96K | 0.00% | −728−65.8% | Reduced |
| Royal Bank of Canada | 133 | $1.00K | 0.00% | +69+107.8% | Added |
| JPMorgan Chase & Co | 11 | $57 | 0.00% | 00.0% | Unchanged |
| Essex Investment Management Co LLC | 0 | $0 | 0.00% | −77,200−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −47−100.0% | Sold out |